Search
Search | Sitemap Contact Sign Up

Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V.

 
DOCKET NO.
21-202
OP. BELOW
Fed. Cir.
SUBJECT
Patent

Question(s) Presented

1. “Does 35 U.S.C. ยง 314(d) categorically preclude appeal of all decisions not to institute inter partes review?”

2. “Is the NHK-Fintiv Rule substantively and procedurally unlawful?”

Posts About this Case

Date
Proceedings and Orders
August 9, 2021
Petition for a writ of certiorari filed. (Response due September 13, 2021)
August 18, 2021
Motion of Andrew Hirshfeld for an extension of time submitted.
August 19, 2021
Motion to extend the time to file a response is granted and the time is extended to and including October 12, 2021, for all respondents.
August 25, 2021
Amicus brief of Jeremy C. Doerre submitted.
September 13, 2021
Amicus brief of Association for Accessible Medicines submitted.
September 13, 2021
Amicus brief of Intel Corporation submitted.
September 30, 2021
Motion of Andrew Hirshfeld for an extension of time submitted.
October 1, 2021
Motion to extend the time to file a response is granted and the time is further extended to and including November 2, 2021, for all respondents.
November 2, 2021
Brief of Janssen Pharmaceutica NV in opposition submitted.
November 2, 2021
Brief of Andrew Hirshfeld in opposition submitted.
November 16, 2021
DISTRIBUTED for Conference of 12/3/2021.
November 16, 2021
Reply of Mylan Laboratories Ltd. submitted.
November 23, 2021
Rescheduled.
December 29, 2021
DISTRIBUTED for Conference of 1/14/2022.
January 18, 2022
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.